• Clinical data 90%
  • Efficacy 80%
  • Security 70%
  • Toxicity 30%

Calendula officinalis
Flos Calendulae


Asteraceae are also known as Compositae.

General appearance

Ligulate florets consist of a yellow, orange or orange-yellow ligule, 3–5mm wide and about 7 mm in the middle part, with 3-toothed apex and hairy, partly sickle-shaped, yellowish-brown to orange-brown tube with projecting style and 2-lobed stigma; occasionally with a partly bent yellowish-brown to orange-brown ovary. Tubular florets about 5 mm long, consist of yellow, orange-red or red-violet 5-lobed corolla and yellowish-brown or orange-brown tube, hairy in its lower part, mostly with a bent yellowish-brown to orangebrown ovary.

Major chemical constituents

The major constituents are triterpene saponins (2–10%) based on oleanolic acid (i.e. calendulosides) and flavonoids (3-O-glycosides of isorhamnetin and quercetin), including astragalin, hyperoside, isoquercitrin and rutin. Other constituents include essential oil, sesquiterpenes (e.g. caryophyllene) and triterpenes (e.g. a- and b-amyrins, lupeol and lupenone). Polysaccharides have also been reported.

Medicinal uses of Calendula officinalis

Uses supported by clinical data
Uses described in pharmacopoeias and in traditional systems of medicine
Calendula officinalis: External treatment of superficial cuts, minor inflammations of the skin and oral mucosa, wounds and ulcus cruris.
Uses described in folk medicine, not supported by experimental or clinical data
Treatment of amenorrhoea, angina, fevers, gastritis, hypotension, jaundice, rheumatism and vomiting.


Experimental pharmacology


Three polysaccharides isolated from an aqueous extract of Flos Calendulae enhanced phagocytosis in human granulocytes in vitro in the colloidal carbon clearance test. Intraperitoneal injection of a polysaccharide fraction isolated from an aqueous extract of the flowers to mice (10 mg/kg body weight) enhanced phagocytosis. Intraperitoneal administration of an unsaponifiable fraction (0.5 ml) of a hydroalcoholic extract of the flowers weakly stimulated phagocytosis in mice inoculated with Escherichia coli. However, the hydroalcoholic extract was not active.

Antimicrobial activity

The essential oil of the flowers inhibited the growth in vitro of Bacillus subtilis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans. A flavonoid fraction isolated from the flowers inhibited the growth in vitro of S. aureus, Sarcina lutea, E. coli, Klebsiella pneumoniae and Candida monosa. However, chloroform, ethanol, methanol or water extracts of the flowers did not inhibit bacterial growth in vitro. Acetone, ethanol or water extracts inhibited the growth in vitro of the fungus Neurospora crassa.
Extracts of the flowers inhibited the growth in vitro of Trichomonas vaginalis.
Oxygenated terpenes appear to be responsible for the antimicrobial activity.

Antiviral activity

A tincture of the flowers suppressed the replication of herpes simplex, influenza A2 and influenza APR-8 viruses in vitro. However, an aqueous extract of the flowers was not active. A chloroform extract of the flowers inhibited
the replication of HIV-1 in acutely infected lymphocytic MOLT-4 cells in vitro (IC50 0.4 mg/ml). A chloroform extract also inhibited HIV-1 reverse transcriptase activity in a dose-dependent manner (ED50 51.0mg/ml) (32). A 5% hot aqueous extract of the flowers (2 ml) inhibited the replication of encephalitis virus after intraperitoneal administration to mice.

Anti-inflammatory activity

Topical application of a 70% ethanol extract of the flowers to mice at a dose of 1.2 mg/ear (corresponding to 4.16 mg crude drug) reduced croton oil-induced ear oedema by 20%. External application of a carbon dioxide extract of the
flowers (300mg/cm2) suppressed croton oil-induced ear oedema in mice. The triterpene fraction of an extract of the flowers had marked antiinflammatory activity in mice (1mg/ear) against ear oedema induced by 12-Otetradecanoylphorbol-13-acetate. Faradiol esters isolated from the flowers (240mg/cm2) inhibited croton oil induced ear oedema in mice. Intragastric administration of an aqueous extract of the flowers (100 mg/kg body weight) inhibited carrageenan-induced footpad oedema in rats. However, an 80% ethanol extract of the flowers was weakly active (11% inhibition) at a concentration of 100 mg/kg body weight administered orally 1 hour prior to induction of oedema. Isorhamnetin glycosides isolated from the flowers inhibited rat lung lipoxygenase in vitro.

Wound-healing activity

External application of a hydroalcoholic extract accelerated the rate of contraction and epithelialization of excision wounds in rats. A 3% freeze-dried aqueous extract of the flowers induced vascularization in the chick chorioallantoic membrane assay. Histological sections of the treated chorioallantoic membranes also indicated the presence of hyaluronan, a tissue glycosaminoglycan associated with neovascularization.

Clinical pharmacology

Although no randomized, controlled clinical trials have been performed, two case reports in the early medical literature support the traditional use of Flos Calendulae. The reports describe the use of a strong tincture of the flowers applied on compresses to reduce inflammation and suppuration, and to accelerate the healing of wounds. These reports may be of historical value only.


Flos Calendulae is contraindicated in cases of known allergy to plants of the Asteraceae (Compositae) family.


No information available.

News and Journals

1. European pharmacopoeia, 3rd ed., Suppl. 2000. Strasbourg, Council of Europe, 1999.
2. British herbal pharmacopoeia. London, British Herbal Medicine Association, 1996.
3. Pharmacopoeia Hungarica, 7th ed. Budapest, Hungarian Pharmacopoeia Commission,
Medicina Konyvkiado, 1986.
4. Boulos L. Medicinal plants of North Africa. Cairo, Reference Publications, 1983.
5. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois
at Chicago, IL, January 28, 1998 production (an online database available
directly through the University of Illinois at Chicago or through the Scientific and
Technical Network [STN] of Chemical Abstracts Services).
6. Bisset NG. Herbal drugs and phytopharmaceuticals. Boca Raton, FL, CRC Press, 1994.
7. Youngken HW. Textbook of pharmacognosy, 6th ed. Philadelphia, PA, Blakiston,
8. Leung AY, Foster S. Encyclopedia of common natural ingredients used in food, drugs, and
cosmetics, 2nd ed. New York, NY, John Wiley & Sons, 1996.
9. Backer CA, Van den Brink B. Flora of Java. Vol. 2. Noordfog-Groningen, NVP, 1965:
10. Pharmacopoea helvetica, 8th ed. Berne, Département fédéral de l’intérieur, 1997.
11. Pharmacopée française. Paris, Adrapharm, 1996.
12. Quality control methods for medicinal plant materials. Geneva, World Health Organization,
13. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996.
14. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World
Health Organization, 1997 (document WHO/FSF/FOS/97.7).
15. Vidal-Ollivier E et al. Dosage par CLHP. Des flavonoides majoritaires de Calendula
officinalis L. En fonction de la variété culturale et de la date de récolte. Pharmaceutica
Acta Helvetiae, 1991, 66:318–320.
16. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris, Lavoisier, 1995.
17. Varljen J, Lipták A, Wagner H. Structural analysis of a rhamnoarabinogalactan
and arabinogalactans with immunostimulating activity from Calendula officinalis.
Phytochemistry, 1989, 28:2379–2383.
18. ESCOP monographs on the medicinal uses of plant drugs. Fascicule 1. Elburg, European
Scientific Cooperative on Phytotherapy, 1996.
19. Blumenthal M et al., eds. The complete German Commission E monographs. Austin, TX,
American Botanical Council, 1998.
20. Wagner H et al. Immunstimulierend wirkende Polysaccharide (Heteroglykane) aus
höheren Pflanzen. Arzneimittel-Forschung, 1985, 7:1069–1075.
21. Delaveau P et al. Drogues végétales stimulant l’activité phagocytaire du système
réticulo-endothélial. Planta Medica, 1980, 40:49–54.
22. Janssen AM et al. Screening for antimicrobial activity of some essential oils by the
agar overlay technique. Pharmaceutisch Weekblad, 1986, 8:289–292.
23. Tarle D, Dvorzak I. Antimicrobial substances in Flos Calendulae. Farmacevtski Vestnik
(Ljubljana), 1989, 40:117–120.
24. Rios JL, Recio MC, Villar A. Antimicrobial activity of selected plants employed
in the Spanish Mediterranean area. Journal of Ethnopharmacology, 1987, 21:139–152.
25. Dornberger K, Lich H. Screening for antimicrobial and presumed cancerostatic plant
metabolites. Pharmazie, 1982, 37:215–221.
26. Acevedo JG, Lopez JL, Cortes GM. In vitro antimicrobial activity of various plant
extracts used by purepecha against some Enterobacteriaceae. International Journal of
Pharmacognosy, 1993, 31:61–64.
27. Kubas J. Investigations on known or potential antitumoral plants by means of microbiological
tests. Part III. Activity of some cultivated plant species in Neurospora crassa
test. Acta Biologica Cracoviensia Series Botanica, 1972, 15:87–100.
28. Racz G et al. Trichomonicidal and anthelmintic activity of Roumanian folkloric
plants. Planta Medica, 1980, 39:257A.
29. Gracza L. Oxygen-containing terpene derivatives from Calendula officinalis. Planta
Medica, 1987, 53:227.
30. Bogdanova NS et al. Study of antiviral properties of Calendula officinalis. Farmakol
Toksikol (Moscow), 1970, 33:349.
31. May G, Willuhn G. Antiviral activity of aqueous extracts from medicinal plants in
tissue cultures. Arzneimittel-Forschung, 1978, 28:1–7.
32. Kalvatchev Z et al. Anti-HIV activity of extracts from Calendula officinalis flowers.
Biomedicine and Pharmacotherapy, 1997, 51:176–180.
33. Fokina GI et al. Experimental therapy of tick-borne encephalitis. Soviet Progress in
Virology, 1991, 1:27–31.
34. Della-Loggia R et al. The role of triterpenoids in the topical anti-inflammatory
activity of Calendula officinalis flowers. Planta Medica, 1994, 60:516–520.
35. Akihisa T et al. Triterpene alcohols from the flowers of Compositae and their antiinflammatory
effects. Phytochemistry, 1996, 43:1255–1260.
36. Zitterl-Eglseer K et al. Anti-oedematous activities of the main triterpendiol esters of
marigold (Calendula officinalis L.). Journal of Ethnopharmacology, 1997, 57:139–144.
37. Peyroux J et al. Anti-oedemic and anti-hyperhaemic properties of Calendula officinalis
L. Plantes médicinales et Phytotherapie, 1981, 15:210–216.
38. Mascolo N et al. Biological screening of Italian medicinal plants for antiinflammatory
activity. Phytotherapy Research, 1987, 1:20–31.
39. Bezakova L et al. Inhibitory activity of isorhamnetin glycosides from Calendula officinalis
L. on the activity of lipoxygenase. Pharmazie, 1996, 51:126–127.
40. Rao SG et al. Calendula and Hypericum: two homeopathic drugs promoting wound
healing in rats. Fitoterapia, 1991, 62:508.
41. Patrick KFM et al. Induction of vascularisation by an aqueous extract of the flowers
of Calendula officinalis L., the European marigold. Phytomedicine, 1996, 3:11–18.
42. Livezey A. Some observations on our indigenous medical flora. Medical and Surgical
Reporter, 1868, 19:85.
43. Reynolds RG. Calendula. Pacific Medical and Surgical Journal, 1886, 29:720.
44. Elias R et al. Antimutagenic activity of some saponins isolated from Calendula
officinalis L., C. arvensis L. and Hedera helix L. Mutagenesis, 1990, 5:327–331.
45. Avramova S et al. Source of new products for the cosmetic industry. Medical and
Biological Information, 1988, 4:28–32.
46. Ramos A et al. Genotoxicity of an extract of Calendula officinalis L. Journal of
Ethnopharmacology, 1998, 61:49–55.
47. Bruynzeel DP et al. Contact sensitization by alternative topical medicaments containing
plant extracts. Contact Dermatitis, 1992, 27:278–279.
48. Willuhn G. Pflanzliche Dermatika, eine kritische Übersicht. Deutsche Apotheker
Zeitung, 1992, 132:1873–1883.
49. Van Hellemont J. Fytotherapeutisch compendium, 2nd ed. Utrecht, Bohn, Scheltema &
Holkema, 1988:113–114.
50. Hänsel R et al., eds. Hagers Handbuch der pharmazeutischen Praxis. Bd. 4: Drogen A–K,
5th ed. Berlin, Springer-Verlag, 1994.